Journament

Keyword Connections - alzheimer Keywords

Connection Type	Connection
Journals	cns & neurological disorders drug targets Environmental research Cells Journal of cellular and molecular medicine artificial intelligence in medicine neurotoxicology Journal of neuroinflammation
Research Groups	No Research Group Connected
Bibliographies	[1] Machine learning and big data: Implications for disease modeling and therapeutic discovery in psychiatry. [2] Molecular mechanism of tumour necrosis factor alpha regulates hypocretin (orexin) expression, sleep and behaviour. [3] The Role of Ca Signaling in Aging and Neurodegeneration: Insights from Models. [4] Alzheimer disease starts in childhood in polluted Metropolitan Mexico City. A major health crisis in progress. [5] Systemic microbial TLR2 agonists induce neurodegeneration in Alzheimer's disease mice. [6] how cholesterol interacts with membrane proteins: an exploration of cholesterol-binding sites including crac, carc and tilted domains [7] effect of creatine supplementation on cognitive performance and apoptosis in a rat model of amyloid-beta-induced alzheimer's disease [8] detection of bacterial antigens and alzheimer’s disease-like pathology in the central nervous system of balb/c mice following intranasal infection with a laboratory isolate of chlamydia pneumoniae [9] multi-target screening and experimental validation of natural products from selaginella plants against alzheimer's disease [10] traditional used plants against cognitive decline and alzheimer disease [11] the cellular prion protein: a player in immunological quiescence [12] the effects of fatty acids of nigella sativa seeds on apoptosis and oxidative stress induced by doxorubicin in pc12 cell line as a neuronal model [13] heterogeneidade cognitiva na doença de alzheimer cognitive heterogeneity in alzheimer's disease [14] additional mechanisms conferring genetic susceptibility to alzheimer's disease [15] el rol de la evaluaciÓn neuropsicolÓgica en el diagnÓstico y en el seguimiento de las demencias [16] alzheimer´s disease: a clinical-practice-oriented review [17] differential processing of natural scenes in typical and atypical alzheimer disease measured with a saccade choice task [18] Measurement of CSF α‐synuclein improves early differential diagnosis of mild cognitive impairment due to Alzheimer’s disease [19] La enfermedad de Alzheimer: importante desafío sociosanitario para el médico de familia [20] Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials [21] Cholinesterase inhibitors for Alzheimer's disease [22] Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease. [23] Alzheimer's disease against peptides products of enzymatic cleavage APP protein: Biological, pathobiological and physico-chemical properties of fibrillating peptides [24] Cholinesterase inhibitors as Alzheimer's therapeutics (Review). [25] Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias. [26] Reconsideration of anticholinesterase therapeutic strategies against alzheimer's disease [27] Stimulation of brain glucose uptake by cannabinoid CB2 receptors and its therapeutic potential in Alzheimer's disease. [28] Synthesis and biological evaluation of flavone-8-acrylamide derivatives as potential multi-target-directed anti Alzheimer agents and investigation of binding mechanism with acetylcholinesterase. [29] Discovery of N-methylpiperazinyl flavones as a novel class of compounds with therapeutic potential against Alzheimer's disease: Synthesis, binding affinity towards amyloid β oligomers (Aβo) and ability to disrupt Aβo-PrP <sup>C</sup> interactions [30] Protection of cholinergic and antioxidant system contributes to the effect of Vitamin D<inf>3</inf> ameliorating memory dysfunction in sporadic dementia of Alzheimer's type [31] Investigation of the Effects of Biochemical Parameters on Alzheimer's Disease. [32] Triazole derivatives as inhibitors of Alzheimer's disease: Current developments and structure-activity relationships [33] Biomarkers for Alzheimer’s Disease in Saliva: A Systematic Review [34] Immunosenescence of Natural Killer Cells, Inflammation, and Alzheimer’s Disease [35] Impaired Cerebral Vasomotor Reactivity in Alzheimer’s Disease [36] Alzheimer’s Disease Mortality according to Socioeconomic Factors: Country Study [37] Alzheimer’s Disease Frontal Cortex Mitochondria Show a Loss of Individual Respiratory Proteins but Preservation of Respiratory Supercomplexes [38] Development of Regional Disparities in Alzheimer’s Disease Mortality in the Slovak Republic from 1996 to 2015 [39] Physician Practice Patterns Associated with Diagnostic Evaluation of Patients with Suspected Mild Cognitive Impairment and Alzheimer’s Disease [40] Longitudinal brain atrophy patterns and neuropsychological performance in older adults with HIV-associated neurocognitive disorder compared with early Alzheimer's disease. [41] The Model of Aging Acceleration Network Reveals the Correlation of Alzheimer's Disease and Aging at System Level. [42] Early Alzheimer's disease-type pathology in the frontal cortex of wild mountain gorillas (Gorilla beringei beringei). [43] Fecal metabolite of a gnotobiotic mouse transplanted with gut microbiota from a patient with Alzheimer's disease. [44] Visual perceptual disorders in Alzheimer's disease. [45] Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease. [46] Meta-Analysis of Gene Expression and Identification of Biological Regulatory Mechanisms in Alzheimer's Disease. [47] Corrigendum to “Fuzzy adaptive cognitive stimulation therapy generation for Alzheimer's sufferers: Towards a pervasive dementia care monitoring platform” (Future Generation Computer Systems (2018) 88 (479–490), (S0167739X1830089X) (10.1016/j.future.2018.06.018)) [48] Promoter Polymorphism-219T/G is an Effect Modifier of the Influence of ε4 on Alzheimer's Disease Risk in a Multiracial Sample. [49] Advance of sporadic Alzheimer's disease animal models. [50] Evaluation of the Music Engagement Program for people with Alzheimer's disease and dementia: Study protocol for a pilot trial. [51] Plasma Neurofilament Light Chain Levels Are Associated With Cortical Hypometabolism in Alzheimer Disease Signature Regions. [52] Molecular Inverse Comorbidity between Alzheimer's Disease and Lung Cancer: New Insights from Matrix Factorization. [53] [Alzheimer's disease and related disorders: specificity of young onset patients, including ethical aspects]. [54] Vitamin D concentration and risk of Alzheimer disease: A meta-analysis of prospective cohort studies. [55] The "rights" of precision drug development for Alzheimer's disease. [56] Probiotic treatment improves the impaired spatial cognitive performance and restores synaptic plasticity in an animal model of Alzheimer's disease. [57] Current State of Digital Biomarker Technologies for Real-Life, Home-Based Monitoring of Cognitive Function for Mild Cognitive Impairment to Mild Alzheimer Disease and Implications for Clinical Care: Systematic Review. [58] Synthesis, biological evaluation, and molecular modeling of nitrile-containing compounds: Exploring multiple activities as anti-Alzheimer agents. [59] Radiosynthesis of carbon-11 labeled PDE5 inhibitors as new potential PET radiotracers for imaging of Alzheimer's disease. [60] Dynamic structural determinants underlie the neurotoxicity of the N-terminal tau 26-44 peptide in Alzheimer's disease and other human tauopathies. [61] White matter alterations in early-stage Alzheimer's disease: A tract-specific study. [62] Risk estimation before progression to mild cognitive impairment and Alzheimer's disease: an AD resemblance atrophy index. [63] Accumulation of Hospital Days Among Antipsychotic Initiators With Alzheimer's Disease. [64] Is Low Psychomotor Speed a Marker of Brain Vulnerability in Late Life? Digit Symbol Substitution Test in the Prediction of Alzheimer, Parkinson, Stroke, Disability, and Depression. [65] Prediction of Alzheimer's disease based on deep neural network by integrating gene expression and DNA methylation dataset [66] Investigation of Cerebral Hemodynamic Changes in Mild Cognitive Impairment Due to Alzheimer’s Disease During a Verbal Fluency Task [67] Automatic detection of alzheimer disease based on histogram and random forest [68] Dysfunction of the ubiquitin ligase E3A Ube3A/E6-AP contributes to synaptic pathology in Alzheimer’s disease [69] Rivastigmine and metabolite analogues with putative Alzheimer’s disease-modifying properties in a Caenorhabditis elegans model [70] Sustained microglial depletion with CSF1R inhibitor impairs parenchymal plaque development in an Alzheimer’s disease model [71] Alzheimer's disease-like pathology-triggered oxidative stress, alterations in monoamines levels, and structural damage of locus coeruleus neurons are partially recovered by a mix of proteoglycans of embryonic genesis [72] Visualizing Alzheimer’s Disease Mouse Brain with Multispectral Optoacoustic Tomography using a Fluorescent probe, CDnir7 [73] Synaptic and memory dysfunction in a β-amyloid model of early Alzheimer's disease depends on increased formation of ATP-derived extracellular adenosine [74] Possible epigenetic regulatory effect of dysregulated circular RNAs in Alzheimer’s disease model [75] Blockade of α4 integrins reduces leukocyte–endothelial interactions in cerebral vessels and improves memory in a mouse model of Alzheimer’s disease [76] Serum and brain natural copper stable isotopes in a mouse model of Alzheimer’s disease [77] Defective autophagy and Alzheimer's disease: Is calcium the key? [78] Differentiating between Alzheimer's disease, amnestic mild cognitive impairment, and normal aging via diffusion kurtosis imaging [79] Optogenetics-induced activation of glutamate receptors improves memory function in mice with Alzheimer's disease [80] Glucocorticoid receptors modulate dendritic spine plasticity and microglia activity in an animal model of Alzheimer's disease [81] Fecal microbiota transplantation alleviated Alzheimer’s disease-like pathogenesis in APP/PS1 transgenic mice [82] Regional mitochondrial DNA and cell-type changes in post-mortem brains of non-diabetic Alzheimer’s disease are not present in diabetic Alzheimer’s disease [83] Reversibility of Age-related Oxidized Free NADH Redox States in Alzheimer’s Disease Neurons by Imposed External Cys/CySS Redox Shifts [84] The effects of insulin and insulin-like growth factor I on amyloid precursor protein phosphorylation in in vitro and in vivo models of Alzheimer's disease [85] Short amylin receptor antagonist peptides improve memory deficits in Alzheimer’s disease mouse model [86] Acute restraint stress reverses impaired LTP in the hippocampal CA1 region in mouse models of Alzheimer’s disease [87] Screening older adults for amnestic mild cognitive impairment and early-stage Alzheimer’s disease using upper-extremity dual-tasking [88] Dual dose-dependent effects of fingolimod in a mouse model of Alzheimer’s disease [89] Electroencephalography reveals lower regional blood perfusion and atrophy of the temporoparietal network associated with memory deficits and hippocampal volume reduction in mild cognitive impairment due to Alzheimer’s disease [90] A comment on effect of plant extracts on Alzheimer′s disease: An insight into therapeutic avenues [91] Legal medical consideration of Alzheimer’s disease patients’ dysgraphia and cognitive dysfunction a 6 month follow up [92] Evaluation of Gene-Based Family-Based Methods to Detect Novel Genes Associated With Familial Late Onset Alzheimer Disease [93] Are TallyHo Mice A True Mouse Model for Type 2 Diabetes and Alzheimer's Disease? [94] Somatic mutation that affects transcription factor binding upstream of CD55 in the temporal cortex of a late-onset Alzheimer disease patient. [95] Commentary: Donepezil enhances understanding of degraded speech in Alzheimer's disease [96] CBIR system using Capsule Networks and 3D CNN for Alzheimer's disease diagnosis [97] Validation of MicroRNA Biomarkers for Alzheimer's Disease in Human Cerebrospinal Fluid. [98] Methylphenidate for Apathy in Community-Dwelling Older Veterans With Mild Alzheimer's Disease: A Double-Blind, Randomized, Placebo-Controlled Trial. [99] Emerging therapeutic potentials of dual-acting MAO and AChE inhibitors in Alzheimer's and Parkinson's diseases. [100] Developments with multi-target drugs for Alzheimer’s disease: an overview of the current discovery approaches [101] Tau Subtypes of Alzheimer's Disease Determined in vivo Using Flortaucipir PET Imaging.